Value20202021202220232024TTMSelling/general/admin expenses23.22 M41.45 M46.07 M52.87 M52.82 M44.43 MResearch & development57.85 M173.76 M147.75 M192.13 M195.16 M131.52 MOperating income71.52 M202.85 M12.18 M78.2 M95.67 M78.35 MNon-Operating Income, Total361 K2.5 M1.02 M16.82 M15.67 M11.93 MInterest expense, net of interest capitalized900 K2.7 M900 K———Non-Operating Income, excl. Interest Expenses-900 K-2.12 M-302 K229 K471 K147 KUnusual income/expense361 K1.92 M420 K16.59 M15.2 M11.79 MPretax income72.41 M204.19 M10.64 M27.89 M80.94 M66.71 MEquity in earnings263 K515 K515 K515 K515 K—Taxes001.29 M1.83 M4 000-792 KNon-controlling/minority interest——————After tax other income/expense—3.38 M2.17 M502 K502 K—Net income before discontinued operations72.15 M203.67 M9.35 M29.73 M80.94 M66.71 MDiscontinued operations——————Net income72.15 M203.67 M9.35 M29.73 M80.94 M66.71 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders72.15 M203.67 M9.35 M29.73 M80.94 M66.71 MBasic earnings per share (Basic EPS)——0.35-1.12-3-2.45Diluted earnings per share (Diluted EPS)——0.35-1.12-3-2.45Average basic shares outstanding——26.45 M26.63 M27 M108.42 MDiluted shares outstanding——27.09 M26.63 M27 M108.42 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)——————
Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025.